The HemOnc Pulse cover image

Part One: The Question of MRD in CLL Therapy

The HemOnc Pulse

00:00

Optimizing Treatment Strategies for Young CLL Patients

This chapter examines the decision-making process for referring a younger CLL patient to cell therapy after failing a BTK inhibitor and showing chemo sensitivity, focusing on CAR-T therapy and MRD monitoring. The discussion evaluates different clinical trials, emphasizing the impact of hazard ratios on treatment decisions and addressing challenges unique to CLL, such as Richter's transformation and immune reconstitution.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app